N-(3-amino-4-fluorophenyl)acrylamide | 1339264-99-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-amino-4-fluorophenyl)acrylamide
• 英文别名: N-(3-amino-4-fluorophenyl)prop-2-enamide
• CAS: 1339264-99-1
• 化学式: C₉H₉FN₂O
• 分子量: 180.182
• InChiKey: JVLUJWWOIGXGOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(3-amino-4-fluorophenyl)acrylamide 在 三乙胺 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 6.0h， 生成 1-(5-acrylamido-2-fluorophenyl)-3-(4-(3-amino-6-phenylisoxazolo[3,4-b]pyridine-4-yl)phenyl)urea
  参考文献：
  名称：

  Discovery of 4‐(4‐aminophenyl)‐6‐phenylisoxazolo[3,4‐ b ]pyridine‐3‐amine derivatives as novel FLT3 covalent inhibitors for the intervention of acute myeloid leukemia

  摘要：

  AbstractSmall molecule covalent drugs have proved to be desirable therapies especially on drug resistance related to point mutations. Secondary mutations of FLT3 have become the main mechanism of FLT3 inhibitors resistance which further causes the failure of treatment. Herein, a series of 4‐(4‐aminophenyl)‐6‐phenylisoxazolo[3,4‐b]pyridine‐3‐amine covalent derivatives were synthesized and optimized to overcome the common secondary resistance mutations of FLT3. Among these derivatives, compound F15 displayed potent inhibition activities against FLT3 (IC50 = 123 nM) and FLT3‐internal tandem duplication (ITD) by 80% and 26.06%, respectively, at the concentration of 1 μM. Besides, F15 exhibited potent activity against FLT3‐dependent human acute myeloid leukemia (AML) cell lines MOLM‐13 (IC50 = 253 nM) and MV4‐11 (IC50 = 91 nM), as well as BaF3 cells with variety of secondary mutations. Furthermore, cellular mechanism assays indicated that F15 inhibited phosphorylation of FLT3 and its downstream signaling factors. Notably, F15 could be considered for further development as potential drug candidate to treat AML.

  DOI：

  10.1002/ddr.22032
• 作为产物：
  描述：

  4-氟-3-硝基苯胺 在 盐酸 、 铁粉 、 碳酸氢钠 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 2.0h， 生成 N-(3-amino-4-fluorophenyl)acrylamide
  参考文献：
  名称：

  [EN] NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY
  [FR] NOUVEAUX DÉRIVÉS FUSIONNÉS DE PYRIMIDINE POUR L'INHIBITION DE L'ACTIVITÉ TYROSINE KINASE

  摘要：

  公开号：

  WO2011162515A3

文献信息

• [EN] COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS<br/>[FR] COMPOSÉS POUR INHIBER LA PROLIFÉRATION CELLULAIRE DANS LES CANCERS INDUITS PAR L'EGFR
  申请人：ARIAD PHARMA INC

  公开号：WO2013169401A1

  公开（公告）日：2013-11-14

  The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula (I), wherein the variables are as defined herein.

  这项发明涉及化合物、药物组合物和治疗EGFR驱动的Formula (I)癌症患者的方法，其中变量如本文所定义。
• NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY
  申请人：Cha Mi Young

  公开号：US20130116213A1

  公开（公告）日：2013-05-09

  The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.

  本发明涉及一种新型融合嘧啶衍生物，具有对酪氨酸激酶的抑制活性，以及一种药物组合物，其作为活性成分用于预防或治疗癌症、肿瘤、炎症性疾病、自身免疫疾病或免疫介导性疾病。
• [EN] PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF<br/>[FR] COMPOSÉS DE PYRIMIDINE, COMPOSITIONS ET LEURS APPLICATIONS MÉDICALES
  申请人：LENGO THERAPEUTICS INC

  公开号：WO2022094354A1

  公开（公告）日：2022-05-05

  The present disclosure relates to a class of pyrimidine compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, stereoisomers, solvates, and hydrates thereof. The present disclosure also relates to a process of preparation of these pyrimidine compounds, pharmaceutical compositions containing them, and medicinal applications thereof.

  本公开涉及一类嘧啶化合物及其立体异构体、互变异构体、药学上可接受的盐、立体异构体、溶剂化物和水合物。本公开还涉及制备这些嘧啶化合物的方法、含有它们的药物组合物以及它们的医药应用。
• NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHD3ITION OF TYROSINE KINASE ACTIVITY
  申请人：Hanmi Science Co., Ltd.

  公开号：EP2585470A2

  公开（公告）日：2013-05-01
• COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS
  申请人：ARIAD PHARMACEUTICALS, INC.

  公开号：EP2704572B1

  公开（公告）日：2015-12-30